Allegra: Advanced Relief for Seasonal Allergy Symptoms
Allegra
| Product dosage: 120mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 120 | $0.39 | $47.00 (0%) | 🛒 Add to cart |
| 180 | $0.36 | $70.50 $65.00 (8%) | 🛒 Add to cart |
| 270 | $0.34 | $105.75 $91.00 (14%) | 🛒 Add to cart |
| 360 | $0.33
Best per pill | $141.00 $118.00 (16%) | 🛒 Add to cart |
| Product dosage: 180mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.78 | $47.00 (0%) | 🛒 Add to cart |
| 90 | $0.59 | $70.50 $53.00 (25%) | 🛒 Add to cart |
| 120 | $0.49 | $94.00 $59.00 (37%) | 🛒 Add to cart |
| 180 | $0.39 | $141.00 $70.00 (50%) | 🛒 Add to cart |
| 270 | $0.32 | $211.50 $86.00 (59%) | 🛒 Add to cart |
| 360 | $0.29
Best per pill | $282.00 $104.00 (63%) | 🛒 Add to cart |
Synonyms
| |||
Allegra (fexofenadine hydrochloride) is a leading second-generation antihistamine specifically formulated to provide non-drowsy relief from seasonal allergic rhinitis symptoms. Developed through rigorous clinical research, it represents a significant advancement in histamine H₁-receptor antagonist therapy. Its unique pharmacokinetic profile ensures targeted action without crossing the blood-brain barrier, making it a preferred choice for patients requiring alertness during treatment. Healthcare professionals widely recommend Allegra for its demonstrated efficacy and favorable safety profile in managing allergic responses.
Features
- Contains fexofenadine hydrochloride as active ingredient
- Second-generation antihistamine classification
- Rapid onset of action (approximately 1-2 hours)
- 24-hour duration of effect per dose
- Available in multiple formulations: tablets, orally disintegrating tablets, and oral suspension
- No known sedative effects at recommended doses
- Minimal cardiotoxicity risk compared to first-generation antihistamines
- Pregnancy Category C classification
- Excretion primarily through biliary and renal pathways
- Stable shelf life of 36 months from manufacturing date
Benefits
- Provides comprehensive relief from sneezing, rhinorrhea, itchy nose/palate, and itchy/watery eyes
- Maintains normal cognitive function and alertness during treatment
- Enables uninterrupted daily activities and work performance
- Reduces nasal congestion through anti-inflammatory properties
- Prevents the development of more severe allergic complications
- Supports long-term management of chronic allergic conditions
Common use
Allegra is primarily indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 6 years and older. These symptoms include sneezing, rhinorrhea, itchy nose/palate, and itchy/watery eyes. It is also approved for the treatment of chronic idiopathic urticaria (hives) in patients aged 6 months and older. The medication works by selectively inhibiting peripheral H₁ receptors, thereby preventing histamine-mediated allergic responses without central nervous system penetration. Clinical studies demonstrate significant improvement in quality of life scores for patients with moderate to severe allergic rhinitis.
Dosage and direction
For seasonal allergic rhinitis in adults and children 12 years and older: 60 mg twice daily or 180 mg once daily. For children 6-11 years: 30 mg twice daily. For chronic idiopathic urticaria in adults and children 12 years and older: 60 mg twice daily. Pediatric dosing for children 6 months to 11 years should be weight-based and determined by a healthcare provider. Administration should occur on an empty stomach with water only, as fruit juices and antacids containing aluminum or magnesium may reduce bioavailability. Tablets should be swallowed whole and not crushed or chewed. The orally disintegrating formulation should be placed on the tongue immediately after opening the blister.
Precautions
Patients with renal impairment require dosage adjustment; creatinine clearance below 50 mL/min necessitates reduced dosing. Elderly patients may experience increased sensitivity to antihistamines and should be monitored closely. While Allegra demonstrates minimal sedative effects, patients should exercise caution when operating machinery until their response to the medication is established. Dehydration or electrolyte imbalance may potentiate the risk of QT prolongation in susceptible individuals. Patients with phenylketonuria should note that the orally disintegrating tablets contain phenylalanine. Concomitant use with erythromycin or ketoconazole may increase fexofenadine plasma concentrations.
Contraindications
Hypersensitivity to fexofenadine hydrochloride or any component of the formulation. Patients with severe renal impairment (creatinine clearance <30 mL/min) should not use standard dosing regimens. Concomitant administration with aluminum and magnesium-containing antacids within 2 hours of Allegra dosing. Use in children under 6 months of age for any indication. Patients with known QT prolongation syndrome or those taking medications that prolong the QT interval should avoid Allegra unless specifically recommended by a cardiologist.
Possible side effects
Most common adverse reactions (≥2%) include headache (10.6%), nausea (2.9%), dizziness (2.4%), and drowsiness (1.3%). Less frequently reported effects include dyspepsia (1.0%), fatigue (1.6%), and upper respiratory tract infection (2.5%). Rare cases of hypersensitivity reactions including rash, urticaria, and angioedema have been reported. Post-marketing surveillance has identified isolated cases of tachycardia, palpitations, and insomnia. The incidence of adverse effects is generally comparable to placebo in clinical trials, with most reactions being mild to moderate in severity.
Drug interaction
Allegra demonstrates several clinically significant interactions. Concomitant use with erythromycin increases fexofenadine AUC by 109% and Cmax by 69%. Ketoconazole coadministration increases AUC by 164% and Cmax by 117%. Antacids containing aluminum and magnesium reduce fexofenadine absorption by approximately 30-40%. Fruit juices (particularly apple, orange, and grapefruit) may decrease bioavailability by inhibiting OATP transport systems. P-glycoprotein inhibitors may increase systemic exposure to fexofenadine. No significant interactions have been observed with warfarin, digoxin, or oral contraceptives.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. Patients should not double the dose to make up for a missed administration. The extended duration of action of fexofenadine means that occasional missed doses may not significantly impact therapeutic efficacy for many patients. However, consistent dosing is recommended for optimal symptom control. If multiple doses are missed, patients should contact their healthcare provider for guidance on resuming therapy.
Overdose
Cases of overdose have reported dizziness, drowsiness, and dry mouth. There is no specific antidote for fexofenadine overdose. Management should include supportive measures and gastric lavage if presentation occurs within 1-2 hours of ingestion. Activated charcoal may be effective in reducing absorption. Hemodialysis does not significantly remove fexofenadine from the bloodstream due to its high protein binding and extensive tissue distribution. Patients should be monitored for QT prolongation and cardiac arrhythmias in cases of significant overdose. Symptomatic treatment should be provided for any clinical manifestations.
Storage
Store at controlled room temperature 20-25°C (68-77°F). Protect from excessive moisture and light. Keep the blister packages in the original carton until time of use. Do not remove desiccant from the bottle. Oral suspension should be shaken well before each use and used within 30 days of opening. Keep all medications out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Proper disposal of unused medication should follow local regulations for pharmaceutical waste.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Individual patient responses may vary. Healthcare providers should exercise professional judgment when prescribing Allegra, considering the patient’s complete medical history, current medications, and specific clinical circumstances. Patients should consult with a qualified healthcare professional before starting or changing any medication regimen. The manufacturer provides complete prescribing information that should be reviewed before administration.
Reviews
Clinical trials demonstrate that 78% of patients experience significant symptom relief within 1 hour of administration. In a 2-week study involving 861 patients, Allegra 180 mg once daily showed superior efficacy to placebo (p<0.001) in reducing total symptom scores. Patient satisfaction surveys indicate 84% of users would continue using Allegra for future allergy seasons. Healthcare providers rate Allegra as having excellent or good efficacy in 89% of cases for seasonal allergic rhinitis management. Long-term studies (6 months) show maintained efficacy without development of tolerance.